Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30055939HIVENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS30055940HIVENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS30055941HIVENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS20040704HPVENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS44043072HTLV-1ENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS44048213HTLV-1ENSG00000186951.17protein_codingPPARANoNo5465Q07869
TVIS44048233HTLV-1ENSG00000186951.17protein_codingPPARANoNo5465Q07869
TCGA Plot Options
Drug Information
GenePPARA
DrugBank IDDB06533
Drug NameRagaglitazar
Target IDBE0000071
UniProt IDQ07869
Regulation Type
PubMed IDs12970088; 16240504
CitationsChakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003 Oct;140(3):527-37. Epub 2003 Sep 1.@@Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB: Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005 Jul-Aug;10(4):295-309.
GroupsInvestigational
Direct ClassificationN-substituted phenoxazines
SMILESCCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC3=C2C=CC=C3)C=C1)C(O)=O
Pathways
PharmGKB
ChEMBLCHEMBL24683